Compounds > 7,7'-(carbonyl-bis(imino-n-methyl-4,2-pyrrolcarbonylimino(n-methyl-4,2-pyrrol)carbonylimino))-bis(1,3-naphthalenedisulfonic acid)
Page last updated: 2024-09-04

7,7'-(carbonyl-bis(imino-n-methyl-4,2-pyrrolcarbonylimino(n-methyl-4,2-pyrrol)carbonylimino))-bis(1,3-naphthalenedisulfonic acid) and Benign Neoplasms

7,7'-(carbonyl-bis(imino-n-methyl-4,2-pyrrolcarbonylimino(n-methyl-4,2-pyrrol)carbonylimino))-bis(1,3-naphthalenedisulfonic acid) has been researched along with Benign Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Vries, EG; Dirix, LY; Fokkema, E; Groen, HJ; Lechuga, MJ; Poggesi, I; van der Graaf, WT; van Oosterom, AT; Wynendaele, W1

Trials

1 trial(s) available for 7,7'-(carbonyl-bis(imino-n-methyl-4,2-pyrrolcarbonylimino(n-methyl-4,2-pyrrol)carbonylimino))-bis(1,3-naphthalenedisulfonic acid) and Benign Neoplasms

ArticleYear
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12

    Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Blood Coagulation; Distamycins; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Patient Selection

2001